Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient in U.S.

Gilead Sciences has priced its COVID-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries, it said on Monday, setting the price of a five-day course at $2,340 per patient. Read More

from Canoe https://ift.tt/3g9Hfps